The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
about
CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohortCYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.
P2860
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
@en
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
@nl
type
label
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
@en
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
@nl
prefLabel
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
@en
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
@nl
P2860
P356
P1476
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
@en
P2093
Danxin Wang
P2860
P304
P356
10.3390/JPM2040175
P577
2012-10-01T00:00:00Z